Recruiting

A Study of Baricitinib in Participants From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis

I4V-MC-JAHV - ClinicalTrials.gov - NCT03773978

The reason for this study is to see if the study drug baricitinib given by mouth is safe and effective in participants with juvenile idiopathic arthritis (JIA) from 2 years to less than 18 years old.
How long will I be in the trial?
The study will last about 44 weeks and may include up to 17 visits.
Email
Recruiting

A Study of Baricitinib in Participants From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis

I4V-MC-JAHV - ClinicalTrials.gov - NCT03773978

The reason for this study is to see if the study drug baricitinib given by mouth is safe and effective in participants with juvenile idiopathic arthritis (JIA) from 2 years to less than 18 years old.
How long will I be in the trial?
The study will last about 44 weeks and may include up to 17 visits.
Email

Key Requirements

Age :

2-17

Sex:

All

Key Requirements

Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.

Age

2-17

Sex

All

Participants must

Participants must have had a diagnosis of any form of JIA, except systemic JIA, before 16 years of age and JIA must be active

Participants must have had an inadequate response to at least one conventional or biologic disease-modifying anti-rheumatic drug (DMARD)

Participants must NOT

Participants must not have systemic JIA, with or without active systemic features

Participants must not have persistent oligoarticular arthritis

Participants must not have been previously treated with a Janus kinase (JAK) inhibitor

Trial Summary

Conditions the trial is for

Systemic Juvenile Idiopathic Arthritis

What the trial is testing?

Baricitinib, Placebo

Could I receive a Placebo?

yes

Enrollment Goal

197

Trial Dates

December 2018 - March 2022

Trial Phase

3

Enter your postal code to find the nearest site

Key Requirements

Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.

Age

2-17

Sex

All

Participants must

Participants must have had a diagnosis of any form of JIA, except systemic JIA, before 16 years of age and JIA must be active

Participants must have had an inadequate response to at least one conventional or biologic disease-modifying anti-rheumatic drug (DMARD)

Participants must NOT

Participants must not have systemic JIA, with or without active systemic features

Participants must not have persistent oligoarticular arthritis

Participants must not have been previously treated with a Janus kinase (JAK) inhibitor

Trial Summary

Conditions the trial is for

Systemic Juvenile Idiopathic Arthritis

What the trial is testing?

Baricitinib, Placebo

Could I receive a Placebo?

yes

Enrollment Goal

197

Trial Dates

December 2018 - March 2022

Trial Phase

3

Not the right fit? Sign up to receive updates on new trials.

Trial Locations

Hide locations not currently recruiting

Enter your postal code to see sites near you

Systemic Juvenile Idiopathic Arthritis Resources

Clinical Trial Participation: What to Expect

Clinical Trial Participation: What to Expect

A clinical trial is a scientific study in people that helps to determine if and how a drug or therapy works. These can also be called clinical studies, or clinical research. Clinical research helps us answer specific questions about an investigational drug , such as: Is it effective? Is it more effective than another established treatment? Is it safe and/or what are its side effects?